In the present study, we demonstrated that the growth factor FGF-23 activates ERK, p38, and JNK signaling, leading to upregulation of LOXL2 and enhanced migratory capacity of osteosarcoma cells. This evidence concerns the gene FGF23 and osteosarcoma.